Nationwide ice cream recall over plastic pieces
Wells Enterprises, Inc. is recalling more than 16,000 gallons of its ice cream and frozen yogurt products due to potential contamination with plastic, according to the U.S. Food and Drug Administration.
Porn would become illegal in US under proposed bill
The voluntary recall, initiated April 25, affects multiple 3-gallon tubs distributed to 103 distribution centers across the United States.
The FDA gave it a Class II recall this week.
Here's how the FDA defines a Class II recall:
a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
The company has notified the distribution centers of the recall.
According to the FDA, no illnesses or adverse reactions have been reported in connection with the affected products.
Another million-dollar home hits the auction block in NE Ohio
Here's the complete list of recalled products:
#
Product Description
Recall Number
Classification
Code Information
Product Quantity
Reason for Recall
1
Rocky Road Flavored Ice Cream, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640050314, Item: 19695
F-0779-2025
Class II
Jet Code: 3G BB PREM ROCKY ROAD 1CS LOT50009 HH 19115 18:00 510 BEST IF USED BY 10/10/26
169 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
2
Mocha Almond Fudge Ice Cream, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640050420, Item: 19702
F-0780-2025
Class II
Jet Code: 3G BB PREM MOCHA ALMOND FUDGE 1CS LOT50016 HH 19115 18:00 5100 BEST IF USED BY 10/09/26
359 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
3
Peanut Butter 'N Fudge Ice Cream, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640050574, Item: 33429
F-0781-2025
Class II
Jet Code: 3G BB PREM PEANUT BTR & FUDGE 1CS LOT50012 HH 19115 18:00 5098 BEST IF USED BY 10/07/26
201 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
4
Country Rich Vanilla Ice Cream, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640600052, Item: 102010
F-0782-2025
Class II
Jet Code: 3G CR VANILLA 1CS LOT50085 HH 19115 18:00 5108 BEST IF USED BY 10/17/26
240 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
5
Scooper Hero Ice Cream, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640050642, Item: 487054
F-0783-2025
Class II
Jet Code: 3G BB PREM SCOOPER HERO 1CS LOT50011 HH 19115 18:00 5087 BEST IF USED BY 09/26/26
726 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
6
Cotton Candy Flavored Ice Cream, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640050482, Item: 662429
F-0784-2025
Class II
Jet Code: 3G BB PREM COTTON CANDY IC 1CS LOT50018 HH 19115 18:00 5099 BEST IF USED BY 10/08/26
39 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
7
GFGB Vanilla Bean Flavored Ice Cream, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640000272, Item: 669740
F-0785-2025
Class II
Jet Code: 3G GFGB VANILLA BEAN 1CS LOT50024 HH 19115 18:00 5093 BEST IF USED BY 4/3/26
120 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
8
Quick Blend Vanilla Flavored Ice Cream, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640050604, Item: 773034
F-0786-2025
Class II
Jet Code: 3G BB QUICK BLEND VANILLA IC 1CS LOT50034 HH 19115 18:00 5098 BEST IF USED BY 10/07/26
280 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
9
Planet Smoothie ZSA Vanilla Flavored Fat Free Frozen Yogurt, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640005567, Item: 889334
F-0787-2025
Class II
Jet Code: 3G PS VANILLA NSA FFFY 1CS LOT50014 HH 19115 18:00 5091 BEST IF USED BY 04/01/26
937 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
10
Johnny Rockets Vanilla Flavored Ice Cream, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640006564, Item: 902486
F-0788-2025
Class II
Jet Code: 3G JRKT VANILLA 1CS LOT50029 HH 19115 18:00 5094 BEST IF USED BY 10/3/26
100 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
11
BIPC Flavored Ice Cream, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640008025, Item: 934085
F-0789-2025
Class II
Jet Code: LOT 50024 HH 19115 18:00 5105 USE BY OCT/14/26
1858 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
12
Vanilla Frozen Yogurt, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 00070640022144, Item: 1352604
F-0790-2025
Class II
Jet Code: 3G SK VANILLA FY 1CS LOT 50002HH 19115 18:00 5091 IF USED BY 9/30/26
5280 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
13
Vanilla Flavored Ice Cream, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640022250, Item: 1355358
F-0791-2025
Class II
Jet Code: 3G PBLY VANILLA ICE CREAM 1CS LOT50005 HH 19115 18:00 5097 BEST IF USED BY 10/06/26
961 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
14
GFGB 12% Vanilla Flavored Ice Cream, 3 GAL, Wells Enterprises, INC dba Wells Dairy, Inc Le Mars, IA 51031, UPC: 070640018451, Item: 1435313
F-0792-2025
Class II
Jet Code: 3G GFGB PREM VANILLA 1CS LOT50004 HH 19115 18:00 5092 IF USED BY 4/2/26
109 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
15
Gordon Choice Vanilla Flavored Ice Cream, 3 GAL, FOR DISTRIBUTION EXCLUSIVELY BY GORDON FOOD SERVICE, WYOMING, MI 49509, UPC: 00093901820730, Item: 1367499
F-0793-2025
Class II
Jet Code: 3G GORDON CHOICE VANILLA 1CS LOT50003 HH 19115 18:00 5093 BEST IF USED BY 10/02/26
1080 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
16
Vanilla Bean Ice Cream with Madagascar vanilla, 3 GAL, DISTRIBUTED BY US FOODS, INC, Rosemont, IL 60018, UPC: 50758108658085, Item: 945313
F-0794-2025
Class II
Jet Code: 3G CHFL VANILLA BEAN 1CS LOT 50026 HH 19115 18:00 5094 IF USED BY 10/3/26
320 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
17
Glenview Farms Vanilla Flavored Ice Cream, 3 GAL, DISTRIBUTED BY US FOODS, INC, Rosemont, IL 60018, UPC: 50758108118398, Item: 785848
F-0795-2025
Class II
Jet Code: 3G GLNV VANILLA 1CS LOT 50066HH 19115 18:00 5105 IF USED BY 10/14/26
1573 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
18
Glenview Farms Chocolate Ice Cream, 3 GAL, DISTRIBUTED BY US FOODS, INC, Rosemont, IL 60018, UPC: 50758108118404, Item: 785855
F-0796-2025
Class II
Jet Code: 3G GLNV CHOCOLATE 1CS LOT 50033HH 19115 18:00 5101 IF USED BY 10/10/26
67 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
19
Glenview Farms Artificially Flavored French Vanilla Ice Cream, 3 GAL, DISTRIBUTED BY US FOODS, INC, Rosemont, IL 60018, UPC: 50758108392668, Item: 785887
F-0797-2025
Class II
Jet Code: 3G GLNV FRENCH VANILLA 1CS LOT 50015HH 19115 18:00 5094 IF USED BY 10/3/26
2261 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
20
Artificially Flavored French Vanilla Ice Cream, 3 GAL, DISTRIBUTED BY SYSCO CORPORATION, HOUSTON, TX 77077UPC: 00074865257275, Item: 1026416
F-0798-2025
Class II
Jet Code: SYS CLSC VANILLA PACKED 03/28/25004011 LOT 50025 HH 19115 18:00 5087 IF USED BY 3/28/26
17 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
21
Keith Valley Vanilla Flavored Ice Cream, 3 GAL, DISTRIBUTED BY Ben E. Keith Foods, Fort Worth, TX 76101 UPC: 046045065871, Item: 1144343
F-0799-2025
Class II
Jet Code: 3G KTHV VANILLA 1CS LOT 50004HH 19115 18:00 5100 IF USED BY 10/9/26
569 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
22
Ellington Farms Vanilla Flavored Ice Cream, 3 GAL, DISTRIBUTED BY Ben E. Keith Foods, Fort Worth, TX 76101 UPC: 046045065833, Item: 1144464
F-0800-2025
Class II
Jet Code: 3G ELLF PREM VANILLA 1CS LOT 50003HH 19115 18:00 5087 IF USED BY 9/26/26
600 3-gallon tubs
Foreign material (plastic) may be present in ice cream product
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
26 minutes ago
- Business Upturn
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
– Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis – KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; 'Cyclacel' or the 'Company'), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, ' Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker ' in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BTC cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. Consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (MCC) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of BTC cells. The authors have also found that BUBR1, a critical mitotic checkpoint protein, may be useful as a biomarker to assess plogosertib's effectiveness. BTC cells with high BUBR1 expression were found to be more sensitive to plogosertib compared to those with low expression. The study concluded that BTC cells with high BUBR1 expression are sensitive to the PLK1 inhibitor plogosertib that demonstrate synergistic effects when combined with an ATR inhibitor, which suggest that targeting PLK1 could be an effective strategy for BTC treatment, especially with BUBR1 expression as a potential biomarker to inform optimal combination therapies. About Biliary Tract Cancer (BTC) BTC, also called cholangiocarcinoma, is a rare but aggressive cancer occurring in the biliary tract, a network of small tubes, or ducts, connecting the liver, gallbladder and small intestine. According to estimates from the National Cancer Institute's SEER database annual US incidence of BTC is 4.4 per 100,000. Prognosis for BTC patients is poor with 5-year overall survival of approximately 10–40% even after surgical tumor resection. BTC treatment strategies include chemotherapy, surgery, radiation and targeted medicines depending on location and stage. As these approaches are not curative, there is an urgent, unmet medical need to treat patients with relapsed, refractory and/or unresectable BTC. About Polo-like Kinase and Plogosertib Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays a central role in cell division or mitosis. PLK1 is an important regulator of the DNA damage cell cycle checkpoint, mitotic entry and exit, spindle formation and cytokinesis, or cell separation into daughter cells. In general, cancer cells, and in particular KRAS mutated and p53(-) cells, are very sensitive to PLK1 depletion. In contrast normal cells with intact cell cycle checkpoints are less sensitive. Pharmacological inhibition of PLK1 in cancer cells blocks proliferation by prolonged mitotic arrest and induces onset of apoptotic death of such cells. Plogosertib (formerly CYC140) is a novel, small molecule, selective and potent PLK1 inhibitor. It has demonstrated impressive efficacy in human tumor xenografts at nontoxic doses. Cyclacel's translational biology program supports the development of plogosertib in solid tumors and leukemias. Preclinical data from independent groups have shown that certain ARID1A- and/or SMARCA-mutated cancers, and cancers associated with DNAJ-PKAc fusions, may benefit from treatment with plogosertib. Additionally, recent data suggest that PLK1 inhibition may be effective in KRAS-mutated metastatic colorectal cancer. PLK1 overexpression correlates with poor patient prognosis in several tumors, including biliary tract, esophageal, fibrolamellar liver, gastric, leukemia, lung, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Initial dose escalation data from a Phase 1 clinical study of oral plogosertib suggest that the compound is well tolerated with no dose limiting toxicity observed in five dosing schedules. Clinical benefit was observed in patients with adenoid cystic, biliary tract, ovarian, and squamous cell sinus cancers. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle and mitosis biology. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit Forward-looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995, and encompasses all statements, other than statements of historical fact contained in this press release. These forward-looking statements can be identified by terminology such as 'may,' 'could,' 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'targets,' 'likely to', 'understands' and similar statements. These forward-looking statements are based on management's current expectations. However, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors and circumstances that may cause Cyclacel's actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments resulting from epidemics or natural disasters, other negative developments in Cyclacel's business or unfavorable legislative or regulatory developments. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements. For a discussion of additional factors that may affect the outcome of such forward-looking statements, see our 2024 annual report on Form 10-K, and in particular the 'Risk Factors' section, as well as the other documents filed with or furnished to the SEC by Cyclacel from time to time. Copies of these filings are available online from the SEC at or on the SEC Filings section of our Investor Relations website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. These forward-looking statements should not be relied upon as representing Cyclacel's views as of any date subsequent to the date of this press release. All forward-looking statements in this press release are based on information currently available to Cyclacel, and Cyclacel and its authorized representatives assume no obligation to update these forward-looking statements in light of new information or future events. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contact Cyclacel Pharmaceuticals, Inc. Email: [email protected] © Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc. 1 Yoojin Jeong, Yoojin Jeong, et al, Abstract 5406: Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker, Cancer Res (2025) 85 (8 Supplement 1): 5406. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
an hour ago
- Yahoo
Compared to Estimates, Vimeo (VMEO) Q2 Earnings: A Look at Key Metrics
Vimeo, Inc. (VMEO) reported $104.65 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 0.3%. EPS of $0.04 for the same period compares to $0.06 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $105.76 million, representing a surprise of -1.05%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Vimeo performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: ARPU - Self-Serve: $197.00 versus $189.45 estimated by two analysts on average. ARPU - Vimeo Enterprise: $24,705.00 compared to the $25,001.00 average estimate based on two analysts. Revenue- Self-Serve: $57.56 million versus the two-analyst average estimate of $56.4 million. Revenue- Vimeo Enterprise: $25 million versus the two-analyst average estimate of $26.3 million. The reported number represents a year-over-year change of +24.7%. Revenue- Other: $1.63 million compared to the $1.79 million average estimate based on two analysts. The reported number represents a change of -89.6% year over year. Revenue- Add-Ons: $8.2 million versus the two-analyst average estimate of $8.15 million. Revenue- OTT: $12.27 million compared to the $12.05 million average estimate based on two analysts. View all Key Company Metrics for Vimeo here>>> Shares of Vimeo have returned -7.1% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vimeo, Inc. (VMEO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
SEMrush Holdings, Inc. (SEMR) Lags Q2 Earnings Estimates
SEMrush Holdings, Inc. (SEMR) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -37.50%. A quarter ago, it was expected that this company would post earnings of $0.07 per share when it actually produced earnings of $0.07, delivering no surprise. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. SEMrush, which belongs to the Zacks Internet - Software industry, posted revenues of $108.89 million for the quarter ended June 2025, in line with the Zacks Consensus Estimate. This compares to year-ago revenues of $90.95 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. SEMrush shares have lost about 28.5% since the beginning of the year versus the S&P 500's gain of 6.1%. What's Next for SEMrush? While SEMrush has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for SEMrush was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.09 on $114.98 million in revenues for the coming quarter and $0.35 on $449.65 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Broadridge Financial Solutions (BR), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 5. This technology outsourcing company is expected to post quarterly earnings of $3.51 per share in its upcoming report, which represents a year-over-year change of +0.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Broadridge Financial Solutions' revenues are expected to be $2.05 billion, up 5.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report SEMrush Holdings, Inc. (SEMR) : Free Stock Analysis Report Broadridge Financial Solutions, Inc. (BR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
